Rossetti, B., Gagliardini, R., Meini, G., Sterrantino, G., Colangeli, V., Re, M. C., . . . De Luca, A. (2017). Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One.

Rossetti, Barbara, et al. "Switch to Maraviroc With Darunavir/r, Both QD, in Patients With Suppressed HIV-1 Was Well Tolerated but Virologically Inferior to Standard Antiretroviral Therapy: 48-week Results of a Randomized Trial." PLoS One 2017.

Rossetti, Barbara, et al. "Switch to Maraviroc With Darunavir/r, Both QD, in Patients With Suppressed HIV-1 Was Well Tolerated but Virologically Inferior to Standard Antiretroviral Therapy: 48-week Results of a Randomized Trial." PLoS One 2017.